<DOC>
	<DOCNO>NCT00320229</DOCNO>
	<brief_summary>The aim study demonstrate , percutaneous coronary intervention , even small amount abciximab standard dose , inject locally , could achieve rapid thrombus resolution clinical improvement without concomitant difference hemorrhagic complication</brief_summary>
	<brief_title>Half-Dose Intracoronary Abciximab Bolus Improves Mortality Outcome Compared Standard Intravenous Regimen</brief_title>
	<detailed_description>Patients acute myocardial infarction unstable angina prone extensive intracoronary thrombosis , lead acute deterioration percutaneous coronary intervention thrombosis device despite therapy . Intracoronary use abciximab report favourable result . We randomly assign 84 patient intracoronary half abciximab bolus ( group A ) standard regimen ( group B ) .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>present unstable angina present acute myocardial infarction eligibility percutaneous coronary intervention present cardiogenic shock</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>angioplasty</keyword>
	<keyword>stent</keyword>
	<keyword>abciximab</keyword>
	<keyword>Platelet Glycoprotein GPIIb-IIIa Complex</keyword>
	<keyword>myocardial infarction</keyword>
</DOC>